Condition (MeSH)
Ileitis
ClinicalTrials.gov lists 52 trials for Ileitis or a narrower condition beneath it. Tel-Aviv Sourasky Medical Center has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
4 of the 52 trials are tagged with Ileitis itself; the rest are tagged with a narrower condition beneath it.
When did Ileitis trials start? (17)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 8
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 2 |
| 2024 | 4 |
| 2023 | 1 |
| 2022 | 2 |
| 2021 | 5 |
| 2020 | 5 |
| 2019 | 8 |
| 2018 | 3 |
| 2017 | 1 |
Showing 10 of 17 earlier years.
No forecast is made for this condition: it averages 2.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 9 trials still running at the 2026-10-09 snapshot; registered median of 24 months across 27 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Ileitis trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 5 |
| Phase 1/2 | 4 |
| Phase 2 | 11 |
| Phase 2/3 | 1 |
| Phase 3 | 6 |
| Phase 4 | 6 |
| Not applicable | 12 |
| Observational | 7 |
How many Ileitis trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 7 |
| Active, not recruiting | 1 |
| Completed | 20 |
| Suspended | 2 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Ileitis trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Tel-Aviv Sourasky Medical Center | 3 |
| Ocera Therapeutics | 2 |
| Takeda | 2 |
| Applied Molecular Transport | 1 |
| Atlantic Pharmaceuticals Ltd | 1 |
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Fecal Microbiota Transplantation | 4 |
| Aqueous activated charcoal | 2 |
| Vedolizumab IV | 2 |
| 5-ASA | 1 |
| Lumbar puncture | 1 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Ileitis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pouchitis | 3 | 1 |
| Crohn's disease | 2 | 1 |
| Abdominal pain | 1 | 1 |
| Anal Absess | 1 | 1 |
| Basal cell carcinoma | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Ileitis? (43)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| T cell clonal expansions in ileal Crohn's disease are associated with smoking behaviour and postoperative recurrence. | Gut | 2019 | Yes |
| Should We Divide Crohn's Disease Into Ileum-Dominant and Isolated Colonic Diseases? | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2019 | Yes |
| Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis. | Annals of the rheumatic diseases | 2017 | Yes |
| Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. | Gastroenterology | 2014 | Yes |
| A family study of asymptomatic small bowel Crohn's disease. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2014 | Yes |
Showing 5 of 43 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.